Fig 1.
Study sample (flow diagram).
Table 1.
Baseline characteristics and disease activity of patients in the study population according to treatment.
Table 2.
Utility gain and effectiveness of different biologics at 6 months follow-up.
Fig 2.
Drug survival, stratified by drug.
The graph for the Kaplan-Meier estimated survival has been censored when the number at risk was below 10. The number of patients on a drug at different time points is listed below the figure.
Fig 3.
Drug survival, stratified by anti-TNF naive, anti-TNF switchers and other modes of action switchers (OMA switchers) in biologic monotherapy.
The graph for the Kaplan-Meier estimated survival has been censored when the number at risk was below 10. The number of patients on a drug at different time points is listed below the figure.
Fig 4.
Drug survival, stratified by 1st, 2nd and 3rd line biologic monotherapy.
The graph for the Kaplan-Meier estimated survival has been censored when the number at risk was below 10. The number of patients on a drug at different time points is listed below the figure.
Table 3.
Utility gain and effectiveness of anti-TNF naïve, anti-TNF switchers and other modes of action (OMA) bDMARDs 6 months follow-up.